European ScreeningPort, the European Centre for Drug Discovery, and Greiner Bio-One GmbH, a leading international technology partner for the diagnostic and pharmaceutical industry, are cooperating to optimise the screening process at ESP’s facility in Hamburg, Germany.
European ScreeningPort offers an infrastructure and marketplace to its academic partners which includes bioassay development and validation, primary screening of small molecules, high content screening for secondary and selectivity assays, and bioinformatics and virtual screening.
Under the terms of the cooperation, ESP will use microplates from Greiner Bio-One as the first choice format for assay development and screening on its state-of-the-art screening equipment. The high quality of their products makes Greiner Bio-One the logical choice as a technology partner. A key benefit to ESP, which screens targets from multiple diverse academic and not-for-profit organisations, is the ability to standardise the screening process by using a consistent source of microplates. The impact of standardisation will be reduced cycle times and increased overall process robustness and reproducibility.
European ScreeningPort GmbH is a public-private partnership founded by the City of Hamburg and Evotec AG and sponsored by the German Ministry of Education and Research (BMBF). The BMBF is providing funding for 5 initial screens, both biochemical and cell-based, in areas such as oncology and infectious diseases. In the future, ESP plans to perform an average of 15 screens/year, with a focus on high content screening and imaging.